A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms CASCADE
- Sponsors AstraZeneca AB
- 19 Nov 2019 Planned End Date changed from 11 Jan 2021 to 16 Oct 2020.
- 19 Nov 2019 Planned primary completion date changed from 11 Jan 2021 to 16 Oct 2020.
- 26 Nov 2018 Status changed from not yet recruiting to recruiting.